E. Flochová

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial

L. Pleyer, R. Greil, U. Jäger, 2019, Cancer medicine.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

L. Pleyer, R. Greil, U. Jäger, 2016, The Lancet. Haematology.

Clinical Laboratory Method for Detection of IGHV Mutation Status in Patients with CLL Validated by Igblast and IMGT/V-QUEST

L. Plank, D. Ilencikova, T. Burjanivová, 2011 .

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

S. Mustjoki, K. Porkka, A. Kreutzman, 2011, PloS one.

Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

R. Greil, U. Jäger, M. Steurer, 2014 .

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

R. Hájek, T. Jelínek, E. Králíková, 2019, Neoplasma.